Healthcare providers and industry analysts expressed serious concerns following President Donald Trump’s announcement of extensive tariff measures that will affect medical supplies and equipment across the board. The new policy, revealed Wednesday, implements a universal 10% tariff starting April 5, with additional country-specific duties beginning April 9.
The sweeping changes will impact essential medical items ranging from basic supplies like catheters and needles to sophisticated diagnostic equipment and glucose monitoring devices. While pharmaceuticals received exemptions, medical device manufacturers and healthcare facilities face significant challenges ahead.
Industry experts warn that the tariffs could severely disrupt healthcare delivery and increase operational costs. According to Fitch Ratings’ Kevin Holloran, healthcare providers will struggle to absorb these additional expenses due to existing fixed-rate contracts with payers, potentially leading to reduced operating income.
The American Hospital Association (AHA) had previously sought exemptions for medical supplies, arguing that many supply chains couldn’t easily be relocated to domestic sources. Both the AHA and AdvaMed, a major medical device industry group, continue pushing for medical device exemptions from the tariffs.
Providence healthcare system estimates the new tariffs could increase their annual costs by $10-25 million. CEO Erik Wexler emphasized that these changes come at a particularly vulnerable time, citing recent supply chain disruptions from Hurricane Helene’s impact on IV solution manufacturing and potential Medicaid funding reductions.
The Florida Hospital Association’s Mary Mayhew highlighted the complexity of the situation, noting that hospitals face limited options for supply chain adjustments due to tight margins and existing group purchasing organization arrangements. Similarly, the Medical Group Management Association’s Anders Gilberg expressed concern about physician practices’ ability to weather additional cost pressures, particularly following recent Medicare reimbursement reductions.
Diabetes technology companies appear particularly vulnerable to the new tariffs. Morningstar analyst Debbie Wang identified Dexcom, Insulet, and especially Tandem Diabetes as companies likely to face significant challenges, given their reliance on international manufacturing and components.
Larger medical device manufacturers, including Boston Scientific and Edwards Lifesciences, are expected to mitigate impact through manufacturing relocations. However, Jefferies analysts note that finding alternative manufacturing locations may prove difficult given the tariffs’ broad scope, though companies with existing operations in Mexico or Canada may fare better as these countries are exempt from new levies.
While some healthcare providers may find temporary shelter from immediate price increases due to existing contracts, as noted by J.P. Morgan analysts, the long-term implications remain concerning. Northwell Health, for instance, anticipates delayed effects due to current contract protections.
William Blair analysts predict that the full impact on medical device costs will become clearer in 2026 as purchasing contracts come up for renewal. The longer-term outlook remains uncertain, dependent on factors such as tariff duration, potential exemptions, and overall healthcare demand.
The situation represents unprecedented territory for healthcare providers and medical device manufacturers, who must now navigate complex supply chain decisions while maintaining quality patient care. As FHA’s Mayhew noted, the constantly evolving nature of the tariff situation makes it particularly challenging for healthcare
organizations to develop effective long-term strategies.
Be First to Comment